Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3903813rdf:typepubmed:Citationlld:pubmed
pubmed-article:3903813lifeskim:mentionsumls-concept:C0041671lld:lifeskim
pubmed-article:3903813lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3903813lifeskim:mentionsumls-concept:C0772277lld:lifeskim
pubmed-article:3903813pubmed:issue1lld:pubmed
pubmed-article:3903813pubmed:dateCreated1985-12-20lld:pubmed
pubmed-article:3903813pubmed:abstractTextNineteen patients meeting the criteria for attention deficit disorder, residual type (adult hyperactivity), were given a 2-week double-blind crossover of DL-phenylalanine versus placebo. Thirteen subjects completed the study; the mean global rating of improvement approached significance as compared with placebo. A significant improvement was noted on mood and mood lability. The phenylalanine responders were then continued on open drug, but lost all positive benefits within 3 months. A later open trial of L-phenylalanine produced no clinical effect.lld:pubmed
pubmed-article:3903813pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3903813pubmed:languageenglld:pubmed
pubmed-article:3903813pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3903813pubmed:citationSubsetIMlld:pubmed
pubmed-article:3903813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3903813pubmed:statusMEDLINElld:pubmed
pubmed-article:3903813pubmed:monthSeplld:pubmed
pubmed-article:3903813pubmed:issn0165-1781lld:pubmed
pubmed-article:3903813pubmed:authorpubmed-author:WenderP HPHlld:pubmed
pubmed-article:3903813pubmed:authorpubmed-author:WoodD RDRlld:pubmed
pubmed-article:3903813pubmed:authorpubmed-author:ReimherrF WFWlld:pubmed
pubmed-article:3903813pubmed:issnTypePrintlld:pubmed
pubmed-article:3903813pubmed:volume16lld:pubmed
pubmed-article:3903813pubmed:ownerNLMlld:pubmed
pubmed-article:3903813pubmed:authorsCompleteYlld:pubmed
pubmed-article:3903813pubmed:pagination21-6lld:pubmed
pubmed-article:3903813pubmed:dateRevised2008-4-17lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:meshHeadingpubmed-meshheading:3903813-...lld:pubmed
pubmed-article:3903813pubmed:year1985lld:pubmed
pubmed-article:3903813pubmed:articleTitleTreatment of attention deficit disorder with DL-phenylalanine.lld:pubmed
pubmed-article:3903813pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3903813pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3903813pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3903813pubmed:publicationTypeControlled Clinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3903813lld:pubmed